Literature DB >> 8556484

Evaluation of an animal model system for cryptosporidiosis: therapeutic efficacy of paromomycin and hyperimmune bovine colostrum-immunoglobulin.

S Tzipori1, W Rand, J Griffiths, G Widmer, J Crabb.   

Abstract

Several immunodeficient rodent models currently exist in which persistent, largely asymptomatic, Cryptosporidium parvum infections can be established. Piglets, in contrast, develop a self-limiting diarrheal illness. We have consequently developed an animal model system in which scid mice were used to screen drugs for inhibitory activity against C. parvum, after which the drugs' therapeutic potential was evaluated with piglets. Paromomycin and hyperimmune bovine colostrum-immunoglobulin were selected to evaluate this system. C. paravum infections in suckling scid mice tended to be associated with villus surfaces, while in weaned and in older scid mice infections were more commonly localized in abscessed crypts. Rates of oocyst shedding in suckling scid mice were 50 to 200 times higher than in weaned mice and therefore made suckling mice a considerably more sensitive model for drug testing. Paromomycin given in high doses over 9 to 10 days was not toxic to either scid mice (3,000 mg/kg of body weight per day) or piglets (500 mg/kg/day). Paromomycin treatment was very effective against villus surface infections in suckling mice and considerably less effective against infections in inaccessible sites such as abscessed crypts and stomach pits seen in weaned and adult scid mice. The therapeutic efficacy of paromomycin in piglets depended on the severity of the diarrheal illness. Mild to moderate diarrhea and infection were cleared after paromomycin treatment of piglets infected with one C. parvum isolate. However, paromomycin had no impact on severely affected piglets infected with a second isolate, presumably because of a rapid transit time through the gut. In contrast to paromomycin hyperimmune bovine colostrum-immunoglobulin treatment reduced the rate of C. parvum infection moderately in scid mice and only slightly in piglets, again probably because of a rapid transit time through the gut and inactivation in the stomach. It was also clear that the impact of effective drugs against C. parvum can be detected within 5 days after the onset of treatment in either model.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8556484      PMCID: PMC368287          DOI: 10.1128/cdli.1.4.450-463.1994

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  37 in total

1.  Chronic Cryptosporidium parvum infections in congenitally immunodeficient SCID and nude mice.

Authors:  J R Mead; M J Arrowood; R W Sidwell; M C Healey
Journal:  J Infect Dis       Date:  1991-06       Impact factor: 5.226

2.  Remission of diarrhoea due to cryptosporidiosis in an immunodeficient child treated with hyperimmune bovine colostrum.

Authors:  S Tzipori; D Roberton; C Chapman
Journal:  Br Med J (Clin Res Ed)       Date:  1986-11-15

3.  Effects of colostral antibody on susceptibility of calves to Cryptosporidium parvum infection.

Authors:  J A Harp; D B Woodmansee; H W Moon
Journal:  Am J Vet Res       Date:  1989-12       Impact factor: 1.156

4.  Immunotherapeutic efficacy of bovine colostral immunoglobulins from a hyperimmunized cow against cryptosporidiosis in neonatal mice.

Authors:  R Fayer; A Guidry; B L Blagburn
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

5.  Anti-Cryptosporidium parvum antibodies inhibit infectivity in vitro and in vivo.

Authors:  P S Doyle; J Crabb; C Petersen
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

6.  Kinetics of Cryptosporidium parvum sporozoite neutralization by monoclonal antibodies, immune bovine serum, and immune bovine colostrum.

Authors:  L E Perryman; M W Riggs; P H Mason; R Fayer
Journal:  Infect Immun       Date:  1990-01       Impact factor: 3.441

7.  Giardia lamblia and Cryptosporidium infections in child day-care centers in Fulton County, Georgia.

Authors:  D G Addiss; J M Stewart; R J Finton; S P Wahlquist; R M Williams; J W Dickerson; H C Spencer; D D Juranek
Journal:  Pediatr Infect Dis J       Date:  1991-12       Impact factor: 2.129

8.  Cryptosporidium: different behaviour in calves of isolates of human origin.

Authors:  E Pozio; M A Gomez Morales; F M Barbieri; G La Rosa
Journal:  Trans R Soc Trop Med Hyg       Date:  1992 Nov-Dec       Impact factor: 2.184

9.  Persistent Cryptosporidium infection in congenitally athymic (nude) mice.

Authors:  J Heine; H W Moon; D B Woodmansee
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

10.  Use of paromomycin for treatment of cryptosporidiosis in patients with AIDS.

Authors:  C J Fichtenbaum; D J Ritchie; W G Powderly
Journal:  Clin Infect Dis       Date:  1993-02       Impact factor: 9.079

View more
  44 in total

1.  Confirmation of the prophylactic value of paromomycin in a natural outbreak of caprine cryptosporidiosis.

Authors:  E H Johnson; J J Windsor; D E Muirhead; G J King; R Al-Busaidy
Journal:  Vet Res Commun       Date:  2000-02       Impact factor: 2.459

2.  Intestinal lesions associated with disseminated candidiasis in an experimental animal model.

Authors:  K A Andrutis; P J Riggle; C A Kumamoto; S Tzipori
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

3.  Infection with Cryptosporidium hominis provides incomplete protection of the host against Cryptosporidium parvum.

Authors:  Abhineet Sheoran; Anthony Wiffin; Giovanni Widmer; Pradeep Singh; Saul Tzipori
Journal:  J Infect Dis       Date:  2012-01-25       Impact factor: 5.226

4.  Validation of IMP dehydrogenase inhibitors in a mouse model of cryptosporidiosis.

Authors:  Suresh Kumar Gorla; Nina N McNair; Guangyi Yang; Song Gao; Ming Hu; Venkatakrishna R Jala; Bodduluri Haribabu; Boris Striepen; Gregory D Cuny; Jan R Mead; Lizbeth Hedstrom
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

5.  Synergistic anticryptosporidial potential of the combination alpha-1-antitrypsin and paromomycin.

Authors:  J R Forney; S Yang; M C Healey
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

6.  Parasites and immunotherapy: with or against?

Authors:  Hossein Yousofi Darani; Morteza Yousefi; Marzieh Safari; Rasool Jafari
Journal:  J Parasit Dis       Date:  2014-08-31

7.  Genetic analysis of a Cryptosporidium parvum human genotype 1 isolate passaged through different host species.

Authors:  D E Akiyoshi; X Feng; M A Buckholt; G Widmer; S Tzipori
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

8.  Sequence polymorphism in the beta-tubulin gene reveals heterogeneous and variable population structures in Cryptosporidium parvum.

Authors:  G Widmer; L Tchack; C L Chappell; S Tzipori
Journal:  Appl Environ Microbiol       Date:  1998-11       Impact factor: 4.792

9.  Detection and genotyping of oocysts of Cryptosporidium parvum by real-time PCR and melting curve analysis.

Authors:  Sultan Tanriverdi; Atila Tanyeli; Fikri Başlamişli; Fatih Köksal; Yurdanur Kilinç; Xiaochuan Feng; Glenda Batzer; Saul Tzipori; Giovanni Widmer
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

10.  The gamma interferon gene knockout mouse: a highly sensitive model for evaluation of therapeutic agents against Cryptosporidium parvum.

Authors:  J K Griffiths; C Theodos; M Paris; S Tzipori
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.